Late Responses in Patients With Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors
Open Access
- 18 July 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (1), 17-23
- https://doi.org/10.1016/j.clml.2021.07.001
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2017
- Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General PopulationJournal of Clinical Oncology, 2016
- Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVLeukemia, 2015
- Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phaseZeitschrift für Krebsforschung und Klinische Onkologie, 2014
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)Blood, 2012
- Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVBlood, 2011
- The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitorsBlood, 2011
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2010
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2006
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2003